Features

Addressing social determinants of health improves outcomes, possibly providing a return on investment. Margins matter, but it’s a long game, often driven by a sense of mission.

To conquer STEMI’s “last frontier,” cardiologists are tapping into an evolving arsenal of strategies while calling for more data and standardized definitions to guide treating physicians.

Cardiologists want solid proof of AI’s efficacy and value. And even then, obstacles to acceptance may remain.

Receiving payments from industry influenced physicians’ device selection but not patient outcomes, according to researchers who analyzed three years of Open Payment Program data.

As new hardware and software are introduced into interventional suites, imaging labs and surgical theaters, who bears responsibility for bringing medical personnel up to speed on the advantages they could deliver for safety and efficacy?

Geisinger is aiming to offer DNA sequencing to all of its 1.5 million patients. Members of its precision health team reveal how the initiative developed and share insights gleaned so far, challenges ahead and questions still to be answered.

A new stem cell-based test may add certainty to efforts to predict whether so-called variants of uncertain significance will contribute to the development of diseases or be harmless. 

Coronary artery calcium scanning is not a Magic 8 Ball, but it is a powerful predictor and a valuable tool for cardiology practices.

I don’t need to tell you that social determinants of health (SDoH) present challenges for your patients. You’ve seen the data indicating that as much as 80 percent of an individual’s health comes from factors other than the clinical care he or she receives. You know the impact of disparities. 

ACC.19 will feature 36 late-breaking clinical trials and clinical research studies, starting with the Apple Heart Study’s findings on the ability of a smartwatch to help identify atrial fibrillation. That question is just one of many the conference will address, says ACC.19 Program Chair Andrew Kates, MD, professor of medicine and director of the cardiology fellowship program at Washington University School of Medicine in St. Louis. During a conversation with Cardiovascular Business, Kates predicted trial highlights and previewed some ACC.19 program innovations. 

Ramping up the battle against cardiovascular disease in women represents a golden opportunity to move the needle on mortality.

The moniker is in flux, but patients, clinicians and organizations are embracing the connectedness of virtual hospitals.